CNCE Concert Pharmaceuticals, Inc.

-0.08  -1%
Previous Close 14.24
Open 14.28
Price To book 4.28
Market Cap 319.48M
Shares 22,562,000
Volume 178,837
Short Ratio 1.70
Av. Daily Volume 477,343

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiation announced May 2, 2017. Noted May 17, 2017 that trial has been placed on clinical hold with FDA requesting non-clinical toxicology data.
Alopecia areata
Phase 2 trial initiation announced December 21, 2016. Data due by end of 2017.
Cystic fibrosis
Phase 3 initiated December 2015. Trial to be completed 3Q 2018
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
Diabetic Kidney Disease

Latest News

  1. Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals
  2. Vertex Undergoes FTC Scrubbing for Deal on CF Treatment
  3. Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act
  4. Concert Pharma Falls After Clinical Hold on Hair Loss Drug
  5. FDA places clinical hold on Concert Pharma's hair loss drug
  6. Hold on Concert's Hair Loss Trials Pushes Shares Down 10%
  7. Concert Pharma stock drops 10% after FDA puts hair loss drug on clinical hold
  8. Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial
  9. ETFs with exposure to Concert Pharmaceuticals, Inc. : May 4, 2017
  10. Concert Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : CNCE-US : May 4, 2017
  11. Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
  12. Edited Transcript of CNCE earnings conference call or presentation 2-May-17 12:30pm GMT
  13. Concert reports 1Q loss
  14. Investor Network: Concert Pharmaceuticals, Inc. to Host Earnings Call
  15. Concert Pharmaceuticals Reports First Quarter 2017 Financial Results
  16. Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
  17. Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences
  18. ETFs with exposure to Concert Pharmaceuticals, Inc. : April 7, 2017
  19. Why Concert Pharmaceuticals Is Music to Investors' Ears
  20. Concert rebuffed $250M buyout offer from Vertex before CF drug deal